| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of intensive glucose lowering in type 2 diabetes.
|
N Engl J Med
|
2008
|
47.90
|
|
2
|
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
|
N Engl J Med
|
2010
|
21.49
|
|
3
|
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
|
N Engl J Med
|
2011
|
15.30
|
|
4
|
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
JAMA
|
2008
|
13.35
|
|
5
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.
|
Am J Cardiol
|
2007
|
9.62
|
|
6
|
Long-term effects of intensive glucose lowering on cardiovascular outcomes.
|
N Engl J Med
|
2011
|
8.14
|
|
7
|
Spironolactone for heart failure with preserved ejection fraction.
|
N Engl J Med
|
2014
|
7.48
|
|
8
|
Erectile dysfunction and subsequent cardiovascular disease.
|
JAMA
|
2005
|
6.22
|
|
9
|
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
|
N Engl J Med
|
2015
|
4.56
|
|
10
|
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
4.21
|
|
11
|
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
|
Diabetes Care
|
2010
|
4.10
|
|
12
|
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
|
JAMA
|
2005
|
3.89
|
|
13
|
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
J Natl Cancer Inst
|
2005
|
2.99
|
|
14
|
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
|
Am J Cardiol
|
2007
|
2.98
|
|
15
|
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials.
|
Circulation
|
2004
|
2.73
|
|
16
|
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
|
J Clin Hypertens (Greenwich)
|
2013
|
2.64
|
|
17
|
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
|
Hypertension
|
2012
|
2.42
|
|
18
|
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.
|
Arch Intern Med
|
2009
|
2.02
|
|
19
|
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.
|
Kidney Int
|
2011
|
1.91
|
|
20
|
Effect of telmisartan on renal outcomes: a randomized trial.
|
Ann Intern Med
|
2009
|
1.85
|
|
21
|
Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis.
|
Circulation
|
2006
|
1.84
|
|
22
|
Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma.
|
Circulation
|
2002
|
1.61
|
|
23
|
Safety profile of extended-release niacin in the AIM-HIGH trial.
|
N Engl J Med
|
2014
|
1.56
|
|
24
|
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).
|
Circulation
|
2011
|
1.52
|
|
25
|
Relationship between coronary artery and descending thoracic aortic calcification as detected by computed tomography: the Multi-Ethnic Study of Atherosclerosis.
|
Atherosclerosis
|
2008
|
1.37
|
|
26
|
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries.
|
Circulation
|
2012
|
1.24
|
|
27
|
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM.
|
Eur J Heart Fail
|
2006
|
1.23
|
|
28
|
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
Clin Trials
|
2005
|
1.21
|
|
29
|
Angiotensin-converting enzyme inhibitors and change in aortic valve calcium.
|
Arch Intern Med
|
2005
|
1.17
|
|
30
|
Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).
|
Am J Kidney Dis
|
2007
|
1.08
|
|
31
|
Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.
|
J Investig Med
|
2004
|
1.05
|
|
32
|
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
|
J Clin Hypertens (Greenwich)
|
2011
|
1.04
|
|
33
|
Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis.
|
Arch Intern Med
|
2008
|
1.00
|
|
34
|
Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population.
|
JACC Cardiovasc Imaging
|
2012
|
0.94
|
|
35
|
Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]).
|
Am J Cardiol
|
2009
|
0.94
|
|
36
|
Relationship between common carotid intima-media thickness and thoracic aortic calcification: the Multi-Ethnic Study of Atherosclerosis.
|
Atherosclerosis
|
2009
|
0.93
|
|
37
|
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
|
J Clin Hypertens (Greenwich)
|
2006
|
0.92
|
|
38
|
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
|
J Gen Intern Med
|
2014
|
0.91
|
|
39
|
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
|
Hypertension
|
2013
|
0.90
|
|
40
|
Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).
|
Am Heart J
|
2009
|
0.90
|
|
41
|
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
|
Am Heart J
|
2007
|
0.88
|
|
42
|
Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial.
|
Clin Trials
|
2010
|
0.85
|
|
43
|
The mini-mental state examination, clinical factors, and motor vehicle crash risk.
|
J Am Geriatr Soc
|
2014
|
0.81
|
|
44
|
Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
|
Eur J Heart Fail
|
2005
|
0.80
|
|
45
|
Age modification of the association of lipoprotein, lipid, and lipoprotein ratio with carotid intima-media thickness (from the Multi-Ethnic Study of Atherosclerosis [MESA]).
|
Am J Cardiol
|
2011
|
0.77
|
|
46
|
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
|
Diabetes Care
|
2015
|
0.75
|
|
47
|
Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
|
N Engl J Med
|
2016
|
0.75
|
|
48
|
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?
|
J Clin Hypertens (Greenwich)
|
2013
|
0.75
|
|
49
|
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
|
J Clin Hypertens (Greenwich)
|
2013
|
0.75
|